


# Pathogenesis of sickle cell disease

---

Professor Irene Roberts

---




# Pathogenesis of sickle cell disease

---

## OBJECTIVES

- Understand the genetics of sickle cell disease
- Understand the pathogenesis of vaso-occlusion in sickle cell disease and how this causes the main clinical presentations of the disease
- To have some insight into the therapeutic implications of understanding the biology of sickling

# Sickling disorders are caused by inheritance of haemoglobin S




sickled  
red cell

reticulocyte

# Main types of Sickle Cell Disease


Name	Hb on HPLC
Sickle cell anaemia HbSS	<b>HbS</b> ,HbF
SC disease (HbSC)	<b>HbS</b> ,HbC,HbF
Sickle $\beta^0$ thalassaemia	<b>HbS</b> ,HbF
Sickle $\beta^+$ thalassaemia	<b>HbS</b> ,HbF,HbA



# Sickle Cell Disease: sickle cell anaemia

INHERITANCE:

Sickle cell anaemia is also known as HbSS



# Molecular Basis of Sickle Cell Disease

---

HbA

HbS

HbS is

$\alpha_2\beta_2^{\text{Val6}}$

CCT GAG GAG

CCT GTG GAG

Pro Glu Glu

Pro Val Glu

5 6 7

5 6 7


$\beta$ -globin<sup>A</sup>

$\beta$ -globin<sup>S</sup>

---

# Sickle Cell Disease: SC disease

## INHERITANCE:




HbC is caused by a  $\beta$ -globin mutation at the same position as HbS:

HbC is  $\alpha_2\beta_2^{\text{Val6}}$

# Sickle Cell Disease: S- $\beta$ -thalassaemia


## INHERITANCE:

Co-inheritance of HbS and  $\beta$ -thal trait: patients have no normal  $\beta$ -globin genes





# Mortality in sickle cell disease




**National Institute of Health  
Cooperative Study of Sickle  
Cell Disease (SCD)**

**The median survival for men  
with HbSS was 42 years and  
for women was 48 years.**

**Platt et al, NEJM 330: 1639, 1994**

# Mortality of children with sickle cell disease



Age	Deaths/ 100 pt yrs
0-2	0.24
2-4	0.43
4-6	1.19
6-8	0.2
8-10	0.0
10-12	0.0
12-14	0.44
14-16	0.88

Quinn et al, 2004

# Pathogenesis of sickling




**Bilateral  
osteonecrosis  
of the hip in  
an 18 year  
old woman  
with sickle  
cell disease**

← hip  
replacement

→ flattening of  
femoral head


# Pathogenesis of Sickling

---




**Cerebral infarcts in a  
20 year old man with  
sickle cell disease**

# Pathogenesis of sickling (vaso-occlusion)



# Vascular occlusion in sickle cell disease

---




- \* Polymerization of HbS within cells
- \* Due to formation of Hb tetramers by deoxy HbS
- \*  $\beta$ S Val<sup>6</sup> fits into a hydrophobic pocket on adjacent tetramers ( $\beta$ A Glu<sup>6</sup> does not)



# Pathogenesis of Sickling








**Deoxy HbS: polymerisation of Hb tetramers as  $\beta$ S Val6 fits into hydrophobic pocket on adjacent tetramers**



**HbS polymers seen by X-ray diffraction**




# Pathogenesis of Sickling





# Vascular occlusion in sickle cell disease

---




- \* Polymerization of HbS within cells
- \* Due to formation of Hb tetramers by deoxy HbS
- \*  $\beta^S$  Val<sup>6</sup> fits into a hydrophobic pocket on adjacent tetramers ( $\beta^A$  Glu<sup>6</sup> does not)

**Prevention of polymerization prevents vascular occlusion in sickle cell disease**

# Vascular occlusion in sickle cell disease

---



- \* Polymerization of HbS within cells
- \* Due to formation of Hb tetramers by deoxy HbS
- \*  $\beta$ S Val<sup>6</sup> fits into a hydrophobic pocket on adjacent tetramers ( $\beta$ A Glu<sup>6</sup> does not)

**HbF**  
increases the solubility of HbS


# Role of HbF in ameliorating sickle cell disease

---


- **Natural history**
  - **infants**
  - **mild disease in Saudi Arabia, India and HPFH**
  - **HbF predicts SCD severity**
- **Effects of HbF *in vitro*, eg HbS polymerization**
- **Effects of HbF modulation *in vivo***

# HbF predicts clinical severity in SCD:

## Co-operative Study of Sickle Cell disease (CSSD)



**Acute Chest Syndrome**  
Castro et al, Blood 1994




**Overall survival**  
Platt et al, NEJM, 1994

# Role of HbF in ameliorating sickle cell disease

---

- **Natural history**
  - **infants**
  - **mild disease in Saudi Arabia, India and HPFH**
  - **HbF predicts SCD severity**
- **Effects of HbF *in vitro*, eg HbS polymerization**
- **Effects of HbF modulation *in vivo***


# Sparing effect of HbF on HbS polymerization



- HbF 6%
- HbF 6.3%
- △ HbF 12.5%
- HbF 18.5%
- HbF 25%
- × Hb AS  
(low HbS)

Poillon et al, PNAS 90: 5039-43, 1993

# Vascular occlusion in sickle cell disease



# Adhesion pathways mediating sickle cell adhesion

## Red cells

$\alpha 4\beta 1$  integrin

Sulphated glycans

CD47 (IAP)

CD36 (platelet GpIV)

PhosphatidylSerine

Glycoprotein 1b

Lutheran blood group

## Endothelial / extracellular matrix

VCAM-1, fibronectin

vWF, thrombospondin (TSP),  $\alpha v\beta 3$

vWF, TSP,  $\alpha v\beta 3$  integrin

vWF, TSP,  $\alpha v\beta 3$


vWF, TSP,  $\alpha v\beta 3$

vWF (von Willebrand factor)

laminin



# Pathogenesis of Sickling




**The development  
of vaso-occlusion**

**STEP 1**

**Red cell adhesion  
to the endothelium  
and extracellular  
matrix proteins**

# Pathogenesis of Sickling




**The development of vaso-occlusion**

**STEP 2**

**The role of haemolysis: intravascular haemolysis reduces nitric oxide (NO) bioreactivity**

# Pathophysiology of Sickling




## Depletion of NO

Intravascular haemolysis releases from the red cell into the plasma:

- FREE HAEMOGLOBIN
- ARGINASE
- LDH

# Pathophysiology of Sickling



## Depletion of NO

Intravascular haemolysis releases from the red cell into the plasma:

- **FREE HAEMOGLOBIN** inactivates NO
- **ARGINASE** depletes arginine for NO production
- **LDH-** marker of haemolysis


# Pathogenesis of Sickling

---

## Nitric oxide

- chronic activation of NO
- increased metabolic demand for NO during VOC
- lower NO levels in patients during VOC
- sickle WBC release increased superoxide-> scavenge NO
- decreased endothelial NO synthase

# Pathogenesis of Sickling





## The development of vaso-occlusion

### STEPS 3 AND 4

Proinflammatory state mediated by red cell adhesion and haemolysis leads to leucocyte adhesion (selectins), platelet activation, release of endothelin-1 (ET-1) and scavenging of NO by haemoglobin dimers



# Microvascular changes during sickle crisis



**Cheung, *et al.* Blood 2002**

# Sickle Cell Disease

## VASO-OCCLUSIVE CRISES: clinical features I

---

- Usually present with pain
- Often accompanied by fever
- Bone pain is the most common
- Other sites include lung, liver, spleen and gut
- Distribution of pain depends on age



# Sickle Cell Disease

## VASO-OCCLUSIVE CRISES: clinical features II

**INFANTS**



**Dactylitis**  
**Splenic sequestration**

**CHILDREN**



**Long bones**  
**Acute chest syndrome**

**CHILDREN &  
ADULTS**



**Abdominal pain**  
**Back pain**

# Sickle Cell Disease


## VASO-OCCLUSIVE CRISES III:

---

Crises may be precipitated by:

- dehydration
- infection
- exercise
- cold
- emotional stress

# Pathogenesis of Sickling




**Chronic vascular damage in sickle cell disease**

**STEPS 5 AND 6**

**Proliferation of smooth muscle cells and fibroblasts in the intimal layer; platelet aggregation and progression of luminal narrowing**


# Pathogenesis of Sickling

- STEPS 7 & 8
- Vasculopathy
  - Occlusion



# Sickle Cell Disease

## CHRONIC ORGAN DAMAGE



**CNS:** stroke, occult damage

**Kidneys:** papillary necrosis, renal failure


**Eyes:** retinopathy

**Bones/joints:** osteonecrosis

**Lungs:** chronic lung disease

**Multi-organ failure:** sudden death

# Preventing vascular occlusion in sickle cell disease:






# Vaso-occlusion in sickle cell disease- therapeutic approaches

## Erythrocytes

- modulating HbF
- Mg/Cl conductance blockers

## Platelets/ Coagulation

- anti-platelet drugs
- anticoagulants



## Leucocytes

- hydroxyurea
- anti-inflammatory drugs

## Endothelial cells

- NO
- arginine
- statins
- heparin
- sildenafil
- ET-1 antagonists